Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.